Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alectinib + anlotinib + tirelizumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
This is a three-drug combination comprising alectinib, anlotinib, and tirelizumab. Alectinib is a second-generation oral ALK tyrosine kinase inhibitor used to treat ALK-positive non-small cell lung cancer (NSCLC). Anlotinib is mentioned in the search results as being combined with gefitinib to inhibit the proliferation of EGFR-TKI-resistant NSCLC cells in vitro and tumor angiogenesis in vivo. No specific information about tirelizumab or the efficacy/safety of this particular three-drug combination (alectinib + anlotinib + tirelizumab) is provided in the search results.
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on alectinib + anlotinib + tirelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alectinib + anlotinib + tirelizumab.